Myelofibrosis Clinical Trial Update: The Science Behind JAK Inhibitors

Published on

Topics include: Treatments and Understanding

With the knowledge clinicians are gaining about the driver mutations of myeloproliferative neoplasms (MPNs), JAK inhibitors have become more recognized as a personalized, targeted therapy. But how do JAK inhibitors actually work? Dr. David Snyder from City of Hope explains what these medicines actual inhibit and goes on to discuss different variations of JAK inhibitors. Dr. Snyder shares information about approved JAK inhibitors and others in clinical trials, such as the PAC203 trial for pacritinib.

To find open clinical trial sites for the PAC203 clinical trial, click here.

Sponsorship of this program was provided by CTI BioPharma.

View more programs featuring and

Related Programs

Closing the MPN Treatment Gap: An Update on New JAK Inhibitor Trials

Dr. John Mascarenhas, from Mount Sinai School of Medicine, joined Patient Power to discuss the status of JAK inhibitors in clinical trials, particularly pacritinib.


Everyone’s MPN Is Different: What You Should Know About Genetic Mutations

Should you get a genetic test? Watch as MPN experts Dr. Alison Moliterno and Dr. Stephen Oh explain the driver mutations associated with MPNs and why they are important in MPN treatment.


Factors to Consider When Choosing Treatment for ET, PV and MF

At a recent town meeting in Chicago, Dr. Brady Stein helps viewers understand what should be considered when choosing a treatment plan for those with ET, PV and MF.


Join Our Community Register for Events Read Our Latest Blog

Page last updated on October 26, 2017